Mary L. Disis - Concepedia

Author

Mary L. Disis

Also Known As

Laurence Zitvogel, Lisa H. Butterfield, M DISIS, M Disis, M L DISIS, M L Disis, M. Disis, M. L. Disis, M.L. Disis, MARY L. (NORA) DISIS

656

Publications

36.3K

Citations

H-Index

179

Concepts

All Affiliations

University of Washington Institute of Translational Health Sciences Fred Hutch Cancer Center The University of Texas MD Anderson Cancer Center Providence Portland Medical Center

About

Mary L. Disis is an author at University of Washington specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	80	10.9K
2	Engineering	5	5	559
3	Health Sciences	5	5	216
4	Education	2	2	184
5	Management	2	2	190

Mary L. Disis

162

Publications

18.7K

Citations

H-Index

Page 1

	Year	Citations
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Tyler J. Curiel, George Coukos, Linhua Zou, Nature Medicine Cancer ImmunosurveillanceSpecific RecruitmentT-regulatory CellImmune RegulationImmunology	2004	5K
Gene expression markers of Tumor Infiltrating Leukocytes Patrick Danaher, Sarah Warren, Lucas Dennis, Journal for ImmunoTherapy of Cancer	2017	824
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Keith L. Knutson, Mary L. Disis Cancer Immunology Immunotherapy Tumor ImmunologyCancer ImmunosurveillanceCancer ImmunityT-regulatory CellImmunology	2005	673
Immune Regulation of Cancer Mary L. Disis Journal of Clinical Oncology Cancer ProliferationImmune RegulationImmunologyPathologyImmunoediting	2010	481
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Mary L. Disis, Emanuel Calenoff, Graham McLaughlin, PubMed Breast OncologyImmunologyAntibody ImmunityPathologyHer-2/neu Protooncogene	1994	467
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients Keith L. Knutson, Kathy Schiffman, Mary L. Disis Journal of Clinical Investigation	2001	450
Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines Mary L. Disis, Theodore A. Gooley, Kristine Rinn, Journal of Clinical Oncology	2002	424
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Mary L. Disis, Matthew H. Taylor, Karen Kelly, JAMA Oncology	2019	417
Current Landscape of Immunotherapy in Breast Cancer Sylvia Adams, Margaret E. Gatti‐Mays, Kevin Kalinsky, JAMA Oncology	2019	401
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. Mary L. Disis, Serenella M. Pupa, Julie R. Gralow, Journal of Clinical Oncology	1997	343

Page 1